Lindahl acts as legal adviser to Medivir in a private placement of approximately 140 MSEK
Lindahl has acted as legal adviser to Medivir AB (publ) in connection with a private placement of approximately 140 MSEK to Swedish and international institutional investors.
The issue was oversubscribed and involved both new and existing investors. The capital will primarily be used to commence clinical development of the drug candidate MIV-711 for the new indication of Legg-Calvé-Perthes disease (Perthes disease), a rare and serious paediatric condition for which there are currently no approved drug treatments.
This capital raise enables Medivir to further develop a drug candidate that has the potential to address a significant unmet medical need and create long-term value.
Lindahl's team consisted of Erika Svensson, Theo Biström and Anna Drogou.
About our client Medivir
Medivir is a research-based pharmaceutical company developing innovative therapies for areas with significant unmet medical needs. The company's leading development programmes include fostrox, a liver-targeted chemotherapy for the treatment of liver cancer, and MIV-711 for the treatment of Osteogenesis Imperfecta (congenital brittle bone disease) and Legg-Calvé-Perthes disease. Medivir (Nasdaq Stockholm: MVIR) is listed on the Nasdaq Stockholm Small Cap list.
Do you want to know more? Contact:
Carousel items
-
News articles
7/7/2026
Lindahl included among Sweden's ten most reputable patent firms for the second consecutive year
For the second consecutive year, Lindahl has been named among Sweden's ten most reputable patent law firms by The Patent Lawyer Magazine – a testament to the firm's strong expertise and long-term commitment in intellectual property law.
-
Portraits
7/3/2026
Jesper on business-oriented legal advice in energy: "It is not enough for the advice to be correct"
Lindahl's energy team is recognised in Legal 500 for combining deep regulatory expertise with broad commercial legal experience – find out how they support clients in a rapidly evolving sector.
-
Cases and transactions
7/2/2026
Lindahl advises Nolato on the divestment of its Romanian operations
Lindahl acted as legal adviser to Nolato AB in connection with the divestment of Nolato Romania, a high-volume injection moulding business with annual turnover of SEK 60 million.
-
Knowledge
6/29/2026
The scope of the Swedish FDI Act is expanded – is your business affected?
MCF's new regulation (MCFFS 2026:13) expands the scope of the Swedish FDI Act from 15 July 2026. Is your business affected? Read about the key changes.
-
Read more news and insights?
